Renhe Pharmaceuticals: Subsidiary Phosphoryl Oseltamivir Oral Suspension Obtained Drug Registration Certificate.

On June 15, Renhe Pharmaceutical announced that its subsidiary Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd. has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of oseltamivir phosphate granules for suspension. Oseltamivir phosphate granules for suspension is used for the treatment of type A and type B influenza in adults and children aged 2 weeks and older, as well as for the prevention of type A and type B influenza in people aged 1 year and older. After obtaining the drug registration approval, the company can produce and market the product. However, due to the industry characteristics of pharmaceutical products, the production and specific sales situation of various products/drugs may be affected by factors such as changes in the market environment, resulting in greater uncertainty.